QIAGEN Q1 2021 Investor Presentation

QIAGEN's Q1 2021 investor presentation reporting full-year 2020 results with net sales of $1.87 billion (+23% CER) and adjusted diluted EPS of $2.15, driven significantly by COVID-19 testing demand. The company reaffirms FY 2021 guidance for net sales growth of ~18-20% CER and adjusted EPS of ~$2.42-2.46 CER, reflecting strong operational performance and continued market momentum.